Articles tagged with Liver Cancer
The new technology can reliably distinguish between cancerous and healthy liver tissue, aiding diagnosis and potentially reducing errors in biopsies. The researchers plan to continue measuring fluorescence lifetime parameters in patients with different types of tumors to generate real-time diagnostic classifiers.
Researchers have developed a CRISPR/Cas9 gene editing system to enhance the effectiveness of sonodynamic therapy, allowing tumors to be effectively shrunk in a mouse model of liver cancer. The technology reduces antioxidant defense systems, increasing cancer cell death from the treatment.
Researchers at University of California San Diego found a way to boost innate immunity in liver cancer, making tumors highly responsive to immunotherapy. The combination of anti-PD-L1 antibody and polyIC molecule showed remarkable synergistic effects in liver tumor inhibition.
Researchers at Princeton University have discovered a new compound that can disable the MTDH gene, which is essential for cancer progression and metastasis. The compound shows promise in treating major human cancers, including breast, prostate, lung, and colon cancers.
A cohort study of 165 patients with hepatitis C-related hepatocellular carcinoma found that treating the virus with direct-acting antivirals reduces tumor progression and metastasis. The study showed a 72% reduction in tumor progression and an 88% reduction in risk of death from HCC.
A new analysis of US national data finds that external-beam radiation therapy is a proven treatment option for patients with unresectable liver cancer but is rarely prescribed, with only 3.6% of patients receiving it. The study suggests that institutional and regional practice patterns play a key role in driving treatment decisions.
A study published in The Journal of Nuclear Medicine found that PSMA PET/CT is more accurate than conventional CT in detecting hepatocellular carcinoma metastases. This led to a change in management plans for nearly half of the patients, enabling them to receive effective treatment.
Scientists use modern imaging technology to determine liver cancer subtypes, identifying specific sugar structures that correlate to different subtypes. This approach could lead to earlier detection and more personalized therapies for hepatocellular carcinoma.
A study at Hiroshima University analyzed 160 pediatric liver cancer cases, identifying molecular markers that help understand treatment outcomes. The research found that ASCL2 and IGF2 production play a crucial role in the disease's development, with 'cell of origin' being a premature hepatoblast.
The most common form of liver cancer is on the rise in rural areas, with men aged 60-69 and non-Hispanic Blacks disproportionately affected. Urban areas, however, have seen a decline in HCC rates since 2013, including among younger individuals and certain ethnic groups.
Researchers identified a minimal set of defined factors that can convert normal human fibroblast cells to liver cancer cells, providing a mechanistic proof-of-principle for understanding why certain mutations cause cancer in particular tissues.
Researchers have found that viruses like hepatitis B and C do not always kill infected cells, but instead cause long-term changes. These changes can affect genes related to cell division and metabolism, potentially contributing to increased risk of liver cancer in cured patients.
A novel approach to improve fitness for surgery, known as 'prehabilitation', has been shown to reduce cancer patients' hospital stay by 1.8 days compared to standard care. This study suggests that prehabilitation can benefit patient outcomes and potentially confer a survival advantage.
A Korean population-based cohort study found that cancer, particularly multiple myeloma and leukemia, is associated with an increased risk of kidney failure. The study included approximately 825,000 patients with cancer compared to twice as many without cancer, matched on other characteristics.
A new study by Salk scientists found that time-restricted eating (TRE) confers multiple health benefits, including reduced risk of type 2 diabetes, fatty liver disease, and sepsis, regardless of age and sex. TRE may also protect against infectious diseases like COVID-19 and improve insulin resistance.
Researchers at Johns Hopkins Medicine discovered a combination therapy that allows some advanced liver cancer patients to undergo successful surgical removal of their cancer. The treatment, involving cabozantinib and nivolumab, has shown promising results in shrinking tumors and reducing the risk of recurrence.
A global study estimates that 4% of all newly diagnosed cancers in 2020 are associated with drinking alcohol, with men accounting for more than three-quarters of those cases. Moderate drinking was found to be problematic, contributing to over 103,000 cases.
Bariatric surgery significantly reduces the risk of cancer in individuals with severe obesity and nonalcoholic fatty liver disease (NAFLD), especially obesity-related cancers. The study found a 25% reduction in risk for obesity-related cancers.
Research found that immunotherapy using checkpoint inhibitors does not benefit patients with NASH-related liver cancer, and may even promote tumor growth. The study identified a biomarker to assess treatment efficacy in these patients.
Researchers discovered that varying levels of a DNA repair enzyme called AAG can lead to different outcomes after exposure to NDMA, a probable carcinogen. High levels of AAG can cause tissue damage and cell death, while low levels can result in more cancer mutations.
Advanced liver fibrosis worsens cancer-specific and overall survival in iCCA patients, regardless of surgical resection. Patients with advanced fibrosis are at increased risk of mortality across follow-up periods.
A study published in Cancer found that nearly one-third of Black patients would not have qualified for liver cancer screening using common cirrhosis measures. The researchers also discovered that the tumors in Black patients tended to be larger, more numerous, and more invasive at diagnosis.
A global survey revealed significant disruptions to liver cancer care during the COVID-19 pandemic, including delayed screenings and treatments. The survey found that 87% of participating cancer treatment centers modified their clinical practices, highlighting the need for continued investment in liver oncology nurses and education.
Researchers found a distinctive gut microbiome profile in people with liver cancer linked to non-alcoholic fatty liver disease (NAFLD) that modulates the immune response, promoting cancer survival. This discovery could lead to more effective preventative and therapeutic treatments for NAFLD-related liver cancer.
Researchers developed a risk score to prioritize liver cancer patients for transplantation, accounting for both cancer-related and non-cancer-related factors. The LiTES-HCC score predicts post-transplant survival for hepatocellular carcinoma patients, leading to more efficient allocation of livers.
Researchers at Massachusetts General Hospital have found that reprogramming the connective tissue microenvironment of a liver cancer can inhibit its progression and resistance to chemotherapy. Blocking placental growth factor (PlGF) with antibodies reduces production of connective tissue and increases survival in mice with liver cancer.
A new study found that tumors in the liver siphon off critical immune cells, rendering immunotherapy ineffective. However, coupling immunotherapy with radiotherapy restored immune cell function and led to better outcomes in mice. Researchers are now exploring potential clinical trials to understand the mechanisms at play.
A new treatment combination combining radiofrequency ablation and chemotherapy drug sunitinib significantly reduces tumor growth and extends the life span of mice with liver cancer. The therapy triggers an immune response to target and destroy liver cancer cells.
Osaka University researchers developed a technique to study liver cancer genes in lab mice, identifying a serum biomarker for effective treatment. The study found that FGF19-driven HCC is susceptible to lenvatinib treatment and a specific protein, ST6GAL1, can be used as a biomarker.
A major new study found that men with two copies of the faulty haemochromatosis genes are 10 times more likely to develop liver cancer by age 75 compared to the general population. Researchers call for routine early testing for the iron overload condition.
A recent study published by Shinshu University found that eating less can significantly reduce the risk of liver cancer caused by fatty liver. The research team observed a 41% decrease in liver tumors in mice with hepatitis C virus core gene, simply through dietary restriction.
A study analyzing US cancer data reveals patients from rural regions and lower-income households often have advanced liver cancer at diagnosis and face higher mortality rates. This highlights the need for targeted quality improvement interventions to address healthcare disparities affecting these populations.
Researchers discovered that liver tumors can harness the liver's powers to retrain the immune system and exert its influence on distant cancer cells. Adding a second checkpoint inhibitor in combination therapy may overcome this resistance and increase immunotherapy effectiveness.
Researchers used nationwide cancer mapping statistics to develop a mathematical model that reveals patterns of cancer incidence by remoteness. The study found cancers having higher incidence in remote areas include head and neck, liver, lung, oesophageal, cervical, and uterine cancers.
Researchers have identified a protein PPARα that regulates bile acid metabolism and suppresses the growth of cholangiocarcinoma in mice. The study provides new insights into liver cancer development and suggests potential therapeutic targets.
Scientists have identified a microRNA in obese mouse mothers that increases the odds of liver cancer in their offspring and throughout future generations. The study found that maternal obesity causes susceptibility to liver cancer in offspring, with the severity increasing over generations.
Researchers at Okayama University have developed a model showing how liver cancer stem cells are born from normal stem cells under specific environmental conditions. The study successfully established liver CSCs without genetic manipulation, providing a crucial tool for further research and potential targeted therapies.
A new treatment combination of atezolizumab and bevacizumab has significantly improved survival for people with hepatocellular carcinoma, reducing mortality risk by 42% and increasing cancer response rates. The therapy is being reviewed for FDA approval under a Real-Time Oncology Review pilot program.
A recent study by Florida Atlantic University found that racial inequalities in liver cancer deaths soared after the introduction of hepatitis C drugs in the US. The study showed a significant increase in mortality rates among black Americans, with excess relative deaths increasing from 27.8% to 45.4% between 1998 and 2016.
Researchers at Skoltech and MIT have developed a new combinatorial therapy for liver cancer using a siRNA approach coupled with lipid nanoparticle technology. This treatment caused a significant decrease in tumor load in a mouse model of hepatocellular carcinoma.
A new study found that exercise can prevent the development of liver cancer in obese mice with fatty liver disease. The research suggests that voluntary exercise exerts its protective effects via molecular signaling pathways, including tumor suppressor gene p53 and stress-activated protein kinase JNK1.
Researchers found that personalized cancer outreach using machine learning and targeted interventions can improve return on investment by 74-96%. The study used a randomized field experiment to analyze the effectiveness of different outreach programs, which varied in their impact depending on patient demographics and characteristics.
A new study found increasing global rates of liver cancer, particularly in people aged 30-59 years and 60 years and older, as well as a notable increase in men. The research, published in the journal Cancer, also revealed that hepatitis B vaccinations and obesity are associated with decreased rates of liver cancer in younger adults.
A recent analysis found that low-dose aspirin significantly reduces the risk of liver cancer and mortality from liver disease in high-risk adults. Over an 8-year follow-up, 4.0% of patients who took low-dose aspirin developed liver cancer, compared to 8.3% of nonusers.
Research finds that persistent NRF2 activation may contribute to enlarged liver and fatty liver diseases, affecting over 200 million worldwide. AKT inhibitors show promise in treating hepatomegaly.
Scientists at UNIGE discovered a protein, S100A11, that promotes inflammation and build-up of fibrous tissue in the liver, increasing cancer severity. The presence of S100A11 in blood may enable early detection through simple blood sampling, paving the way for targeted therapies.
A Cedars-Sinai team will investigate the interplay between dietary fat and fatty liver disease to understand how cancer spreads to the liver and find ways to block it. The study aims to identify key mechanisms that allow cancer to spread to the liver and develop potential treatments.
Research reveals that liver cancer tumors contain diverse sets of cells, affecting tumor growth and immune response. A single biopsy may mischaracterize a tumor's genetic makeup and immune cell infiltration.
A pooled analysis of nine studies involving over 750,000 adults found that recommended amounts of leisure-time physical activity were linked to a lower risk for seven cancers. The study suggests that people should aim for moderate- or vigorous-intensity activities for at least 2.5 to 5 hours/week to reduce cancer risk.
Researchers developed a mathematical model that uses RNA sequencing and bioinformatics to identify sudden transcriptomic switches in healthy liver tissue, turning them cancerous. The tool can predict tumor stages and prognosis for patients with liver cancer.
Researchers discover that non-cancerous liver cells around tumors have the capacity to kill nearby tumor cells when hyperactivated, leading to reduced tumor burden and longer survival in mice. The study identifies YAP and TAZ genes as driving this anti-tumor mechanism.
The incidence of liver cancer has tripled in the UK over the past 20 years, with the majority of cases diagnosed in men. The most deprived fifth of the population accounts for 25% of HCC cases, many of which have cirrhosis and are not treatable by surgery due to advanced scarring.
Researchers discovered a new protein, clathrin, involved in liver cancer development and progression. High levels of clathrin expression correlate with the activation of TGF-β pathway, promoting tumor growth and invasion.
Researchers at Charité - Universitätsmedizin Berlin developed a new diagnostic technique using tomoelastography to visualize liver tumor mechanical properties. The study found that hepatic malignancies contain tissues with both stiff and fluid properties, contrary to previous assumptions.
A new study published in Cancer Research found that excess fat in the liver impairs a tumor-suppressing protein named HNF4α, increasing cancer risk. The research provides potential mechanisms for the growing incidence of liver cancer linked to fatty liver disease.
A new study from National University of Singapore (NUS) researchers has demonstrated a potential method for treating advanced liver cancers like hepatocellular carcinoma (HCC). Targeting the JAK/STAT signalling pathway, they found that a class of small molecule drugs can effectively reduce cancer progression in preclinical models, with...
A new blood test can detect liver cancer and life-threatening vascular complications in diabetic patients with high accuracy. The test analyzes DNA in just a few drops of blood and has already shown promise in detecting other major cancers.
A large cohort study confirms that adding transarterial chemoembolization (TACE) to sorafenib improves survival rates in patients with advanced liver cancer, with median overall survival increasing by up to 26%. The treatment combination also shows similar tolerability compared to sorafenib alone.
Researchers from Osaka University have identified a gene, GREB1, as a key player in the development of hepatoblastoma. The study found that suppressing GREB1 production using antisense oligonucleotides significantly reduced tumor formation and cell proliferation in mouse liver cancer models.
Scientists found that Nqo1 is necessary for liver cancer cells' ability to thrive by activating key pathways. Blocking Nqo1 dramatically suppresses liver cancer cell proliferation.